首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1672726

癌症治療市場按分銷管道、藥物類型、癌症類型、治療方法、給藥途徑和地區分類

Oncology Drugs Market, By Distribution Channel, Drug Type, Cancer Type, By Therapy, By Route of Administration, By Geography

出版日期: 2025年02月14日 | 出版商:

Coherent Market Insights | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球抗癌藥物市場規模估計為 2,612.2 億美元，預計到 2032 年將達到 6,073.6 億美元，2025 年至 2032 年的複合年成長率為 12.8%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	2612.2億美元
效能資料	2020-2024	預測期	2025-2032
預測期：2025 年至 2032 年複合年成長率	12.80％	2032 年金額預測	6073.6億美元

圖。

抗癌藥是指用於治療癌性腫瘤的藥物。由於各種癌症發病率的上升，全球抗癌藥物市場在過去幾年一直穩定成長。根據世界衛生組織 (WHO) 的數據，自 2000 年以來，全球癌症發生率幾乎加倍，預計到 2040 年全球整體發生率將增加 50%。肺癌、結腸癌、乳癌和攝護腺癌等癌症發生率上升是推動抗癌藥物需求的主要因素。此外，老年人口的增加以及吸煙、飲酒、飲食不良、缺乏運動等生活習慣的改變也在增加罹患癌症的風險，從而增加癌症治療藥物的銷售量。大量新型藥物分子和治療方法以及標靶治療的出現進一步推動了市場擴張。然而，高昂的治療費用仍是阻礙抗癌藥物廣泛使用的瓶頸。

市場動態

全球抗癌藥物市場受到世界各地各種癌症發生率不斷上升的推動。根據提供全球癌症統計數據的基於網路的互動式平台 GLOBOCAN 的數據，2020 年全球將有約 1,930 萬例新發癌症病例和 1,000 萬人死亡。肺癌仍然是癌症死亡的主要原因。標靶治療的需求不斷成長以及學名藥的易得性為市場提供了巨大的成長機會。然而，嚴格的監管措施、市場開發的高研發成本以及臨床測試的高失敗率是限制市場成長的一些因素。此外，重磅藥物專利到期也對各大公司的收益負面影響。隨著人們認知的提高、醫療支出的增加以及對優質抗癌藥物的需求，亞太地區的新興市場正以巨大的潛力開闢新的道路。

研究的主要特點

本報告對全球腫瘤藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
全球抗癌藥物市場的主要企業已根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行了分析。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
本報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過全球抗癌藥物市場分析中使用的各種策略矩陣更輕鬆地做出決策。

熱圖分析
公司簡介
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Bristol-Myers Squibb
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck &Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo

第 12 章分析師觀點

興衰
一致的機會地圖

第13章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI2332

Global Oncology Drugs Market is estimated to be valued at USD 261.22 Bn in 2025 and is expected to reach USD 607.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 261.22 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	12.80%	2032 Value Projection:	USD 607.36 Bn

Figure. Oncology Drugs Market Share (%), By Region 2025

Oncology drugs refer to medications that are used for treating cancerous tumors. The global oncology drugs market has been witnessing steady growth over the past few years owing to the rising prevalence of various types of cancers. According to the World Health Organization, the cancer burden has nearly doubled since 2000 and is expected to grow by 50% globally by 2040. The increasing incidences of lung cancer, colorectal cancer, breast cancer, and prostate cancer are the major factors fueling the demand for oncology drugs. Furthermore, the growing geriatric population and changing lifestyle habits such as tobacco smoking, alcohol consumption, poor diet, and lack of physical activity have also raised the risk of developing cancer which has augmented the sales of oncology medications. A robust pipeline of novel drug molecules and therapies along with the emergence of targeted therapies are further catalyzing market expansion. However, high treatment cost remains a bottleneck, restraining the broader adoption of cancer medications.

Market Dynamics:

The global oncology drugs market is driven by the rising prevalence of various cancer types worldwide. As per GLOBOCAN, an interactive web-based platform presenting global cancer statistics, there were around 19.3 million new cancer cases and 10 million cancer deaths globally in 2020. Lung cancer remains the leading cause of cancer death. The increasing demand for targeted therapies and easy availability of generic medications are providing huge growth opportunities in the market. However, factors such as stringent regulatory policies, high R&D costs involved in drug development, and frequent drug failures in clinical trials are impeding the market growth. Furthermore, patent expiry of blockbuster drugs is negatively impacting the revenues of major players. Nonetheless, emerging markets in Asia Pacific are opening up new avenues by offering potential future opportunities driven by growing awareness, healthcare spending, and demand for quality cancer treatment.

Key Features of the Study:

This report provides an in-depth analysis of the global oncology drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, BeiGene LTD, Astellas Pharma Inc., AbbVie Inc., Takeda Pharmaceutical Company, and Daiichi Sankyo
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology drugs market

Market Segmentation

Drug Type
- Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
- Targeted Drugs
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Others
- Hormonal Drugs
- Ovarian Function Blockers
- Estrogen Production Blockers
- Others
Cancer Type:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Bladder Cancer
- Other
Therapy:
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
Route of Administration:
- Oral
- Parental
- Intramuscular
- Intravenous
- Subcutaneous
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- F.Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Therapy
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Pipeline Analysis
Patent Expiry List (2018-2031)
Investments for R&D
Reimbursement Scenario
Mergers & Acquisitions
Collaborations
Epidemiology
PEST Analysis

4. Global Oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic:

Overall Impact
COVID-19 Impact on the Market

5. Global Oncology Drugs Market, By Drug Type, 2020 - 2032, (USD BN)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cytotoxic Drug
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Ovarian Function Blockers
Estrogen Production Blockers
Others
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

6. Global Oncology Drugs Market, By Cancer Type,2020 - 2032, (USD BN)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Colorectal Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Blood Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Bladder Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

7. Global Oncology Drugs Market, By Therapy, 2020 - 2032, (USD BN)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

8. Global Oncology Drugs Market, By Route of Administration, 2020 - 2032, (USD BN)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Parental
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Intramuscular
- Intravenous
- Subcutaneous

9. Global Oncology Drugs Market, By Distribution Channel, 2020 - 2032, (USD BN)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

10. Global Oncology Drugs Market, By Region, 2020 - 2032, (USD BN)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
Middle East
Africa

11. Competitive Landscape

Heat Map Analysis
Company Profile
- Pfizer Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Bristol-Myers Squibb
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo